What is the appropriate management for hyperkalemia, including emergent treatment and second‑line options?

Management of Hyperkalemia

For acute hyperkalemia with ECG changes or potassium ≥6.5 mmol/L, immediately administer IV calcium (10 mL of 10% calcium gluconate) to stabilize the myocardium, followed by combination therapy with IV insulin-glucose (10 units insulin + 50 mL dextrose) and nebulized salbutamol (20 mg in 4 mL) to shift potassium intracellularly. 1, 2

Acute Management Algorithm

Step 1: Cardiac Membrane Stabilization (Immediate - within 1-3 minutes)

• IV calcium works within 1-3 minutes to reduce membrane excitation in cardiac tissue 1
• Primary indication: ECG changes OR serum K+ ≥6.5 mmol/L 2
• Critical point: Calcium does NOT lower potassium levels; it only protects the heart temporarily

Step 2: Intracellular Potassium Shift (30-60 minutes onset)

Use combination therapy as it is more effective than either agent alone 1, 3:

• IV insulin-glucose: 10 units regular insulin + 50 mL dextrose 1

  • Major pitfall: High risk of subsequent hypoglycemia, especially in non-diabetic patients with low baseline glucose 2
  • Monitor glucose closely for several hours post-administration

• Nebulized salbutamol: 20 mg in 4 mL 1, 3

  • Provides synergistic effect with insulin
  • Short duration of action (2-4 hours) 1
  • Well-supported by evidence as first-line therapy 3

Step 3: Potassium Elimination

Context-dependent second-line options 1:

• Diuretics (loop or thiazide): Only in hypervolemic, non-oliguric patients with preserved renal function 1, 4

• Sodium bicarbonate IV: Limited to patients with metabolic acidosis 1

  • Evidence remains equivocal for routine use 3

• Hemodialysis: Definitive treatment for:

  • Oliguria or end-stage renal disease 1
  • Refractory acute hyperkalemia 2, 5

Chronic Management and Recurrence Prevention

Preventing recurrent hyperkalemia should be standard practice, as one in five patients with CKD, heart failure, or diabetes will experience recurrence with increasingly shorter intervals between events. 6

Key Management Principles:

• Do NOT discontinue RAASi therapy in patients with CKD or heart failure unless absolutely necessary 1

  • Discontinuation increases mortality and major adverse cardiovascular events 1
  • Maximum RAASi therapy should be maintained when indicated 1

• Potassium binders facilitate RAASi optimization 1

  • Newer agents (sodium zirconium cyclosilicate, patiromer) show promise 2, 5
  • Sodium polystyrene sulfonate is no longer recommended due to questionable efficacy and GI adverse events 2, 4

• Monitoring strategy 1:

  • Check K+ within 7-10 days after starting or increasing RAASi doses
  • Reassess K+ within 1 week after acute hyperkalemia resolution 1
  • Individualize frequency based on comorbidities (CKD stage, diabetes, heart failure)

Risk Assessment and Prevention

All healthcare professionals must evaluate and address recurrence risk at every clinical encounter 6:

• Identify and correct reversible causes (acute kidney injury, metabolic acidosis, medications)
• Remove other risk factors when possible (NSAIDs, potassium-sparing diuretics)
• Consider sodium bicarbonate in CKD patients with acidosis 6
• Implement potassium-wasting diuretics when appropriate 6

Important Caveats

• Pseudohyperkalemia: Rule out hemolysis, poor phlebotomy technique, or delayed specimen processing before treating 1
• Plasma vs serum: Plasma K+ is 0.1-0.4 mmol/L lower than serum due to platelet release during coagulation 1
• Clinical context matters: Focus on hyperkalemia with clinical impact and rapid K+ fluctuations rather than rigid thresholds 1
• Dietary restriction: Low-K+ diet has limited evidence and is difficult to maintain; may reduce beneficial cardiovascular effects of potassium-rich diets 1

Monitoring During Acute Treatment

Track the following 1:

• K+ trajectory with serial measurements
• ECG changes
• Other symptoms (muscle weakness, paresthesias)
• Glucose levels (for hours after insulin administration)